1986
DOI: 10.1016/0006-2952(86)90483-1
|View full text |Cite
|
Sign up to set email alerts
|

Dipyridamole and vascular prostacyclin production

Abstract: The action of dipyridamole on the vascular production of prostacyclin (PGI2) has been investigated. Dipyridamole (1-100 microM) did not induce a significant stimulation of PGI2 release in any of the following experimental models: rings of rabbit aorta, cultured endothelial cells from bovine aorta or human umbilical vein, cultured explants of bovine aortic smooth muscle. The activity of known stimuli of PGI2 release (ADP, suloctidil, serotonin) and the capacity of dipyridamole to inhibit adenosine uptake into e… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
6
0

Year Published

1987
1987
2004
2004

Publication Types

Select...
8
1

Relationship

2
7

Authors

Journals

citations
Cited by 17 publications
(7 citation statements)
references
References 33 publications
(37 reference statements)
1
6
0
Order By: Relevance
“…This is supported by our observation that cAMP elevation, by inhibiting phosphodiesterase activity with dipyridamole, did not influence eicosanoid synthesis (data not shown). This observation is in accordance with Boeynaems et al, 26 who observed that dipyridamole did not influence the ADP-induced biosynthesis of PGI 2 in aortic rings.…”
Section: +supporting
confidence: 82%
“…This is supported by our observation that cAMP elevation, by inhibiting phosphodiesterase activity with dipyridamole, did not influence eicosanoid synthesis (data not shown). This observation is in accordance with Boeynaems et al, 26 who observed that dipyridamole did not influence the ADP-induced biosynthesis of PGI 2 in aortic rings.…”
Section: +supporting
confidence: 82%
“…It inhibits the active uptake of adenosine into cells at low concentration (10-6 M), whereas higher concentrations are required for cyclic AMP phos phodiesterase and adenosine deaminase inhibition (Phillis and Wu, 1982). In addition, no effect on prostacyclin concentrations occur at a concentra tion of 10-6 M (Boeynaems et al, 1986). In this study, we used CSF concentrations of dipyridamole (10-6 M) and theophylline (5 x 10-5 M), which presumably affect primarily adenosine availability and metabolism.…”
Section: Discussionmentioning
confidence: 99%
“…12 Increasing concentrations of cAMP affect platelet-activating factor, collagen, and adenosine diphosphate to inhibit platelet aggregation. 12, 16,17 Dipyridamole also inhibits platelet cyclic-3′,5′-guanosine monophosphate (cGMP) phosphodiesterase, which, in turn, inhibits platelet activation and aggregation. 12 Dipyridamole also stimulates prostacyclin synthesis and potentiates the antiplatelet effects of prostacyclin.…”
Section: Pharmacologymentioning
confidence: 99%